Mira Pharmaceuticals (MIRA) said Thursday it has expanded its pain management portfolio by developing topical formulation of Ketamir-2 to treat localized neuropathic and inflammatory pain.
The topical treatment of Ketamir-2 is developed for "slow release" to directly target the pain site, while also reducing systemic exposure and side effects, the company said, adding that potential applications include neuropathic pain conditions, inflammatory pain conditions, and nerve compression & musculoskeletal pain.
Mira said it is currently carrying out a phase 1 clinical study for the Ketamir-2 oral treatment for neuropathic pain.
MIRA shares were 3% higher ahead of Thursday's opening bell.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.